Press release
Palmoplantar Pustulosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Kyowa Kirin Co., Ltd., Aristea Therapeutics Inc., AnaptysBio, Inc., Boeh
Palmoplantar Pustulosis Pipeline Analysis
DelveInsight reports that over eight key companies are actively involved in developing more than eight treatment therapies for Palmoplantar Pustulosis.
Palmoplantar Pustulosis Overview:
Palmoplantar pustulosis (PPP) is a rare and chronic inflammatory skin condition marked by the formation of sterile pustules-small to large blisters filled with yellowish, cloudy fluid-on the palms of the hands and/or soles of the feet. These pustules can be painful and often produce a burning sensation. The precise cause of PPP is not fully understood, but potential triggers may include smoking, bacterial infections (such as chronic tonsillitis, sinusitis, or dental issues), contact allergies (especially to metals), and certain medications. Common signs include red and tender skin, pustules, itching, pain, cracked or thickened skin, dry patches, and flaking. Although there is currently no cure, treatment options aim to alleviate symptoms and improve quality of life.
Request for a detailed insights report on Palmoplantar Pustulosis pipeline insights @ https://www.delveinsight.com/report-store/palmoplantar-pustulosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Palmoplantar Pustulosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Palmoplantar Pustulosis Therapeutics Market.
Key Takeaways from the Palmoplantar Pustulosis Pipeline Report
*
DelveInsight's Palmoplantar Pustulosis (PPP) pipeline report highlights a dynamic and evolving landscape, with over 8 key companies actively developing more than 8 potential therapies for PPP treatment.
*
Notable companies such as Kyowa Kirin Co., Ltd., Aristea Therapeutics Inc., AnaptysBio, Inc., Boehringer Ingelheim, and Janssen Biotech are leading efforts to advance innovative treatment options.
*
Prominent therapies under development include KHK4827 (Brodalumab), Imsidolimab, and others, which are progressing through various stages of clinical trials.
*
While Spesolimab-an anti-IL-36 receptor antibody-received FDA approval in March 2025 for managing flares in generalized pustular psoriasis (GPP) patients aged 12 and above, it did not demonstrate significant efficacy in a clinical trial targeting PPP, failing to meet its primary endpoint.
Palmoplantar Pustulosis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Palmoplantar Pustulosis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Palmoplantar Pustulosis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Palmoplantar Pustulosis market.
Download our free sample page report on Palmoplantar Pustulosis pipeline insights [https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Palmoplantar Pustulosis Emerging Drugs
*
KHK4827 (Brodalumab): Kyowa Kirin Co. Ltd.
*
Imsidolimab: AnaptysBio, INC.
Palmoplantar Pustulosis Companies
Approximately eight or more major companies are actively engaged in developing treatments for Palmoplantar Pustulosis. Among them, Kyowa Kirin Co., Ltd. has a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.
DelveInsight's report covers around 8+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Palmoplantar Pustulosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Palmoplantar Pustulosis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Palmoplantar Pustulosis Therapies and Key Companies: Palmoplantar Pustulosis Clinical Trials and advancements [https://www.delveinsight.com/report-store/palmoplantar-pustulosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Palmoplantar Pustulosis Pipeline Therapeutic Assessment
- Palmoplantar Pustulosis Assessment by Product Type
- Palmoplantar Pustulosis By Stage
- Palmoplantar Pustulosis Assessment by Route of Administration
- Palmoplantar Pustulosis Assessment by Molecule Type
Download Palmoplantar Pustulosis Sample report to know in detail about the Palmoplantar Pustulosis treatment market @ Palmoplantar Pustulosis Therapeutic Assessment [https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Palmoplantar Pustulosis Current Treatment Patterns
4. Palmoplantar Pustulosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Palmoplantar Pustulosis Late-Stage Products (Phase-III)
7. Palmoplantar Pustulosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Palmoplantar Pustulosis Discontinued Products
13. Palmoplantar Pustulosis Product Profiles
14. Palmoplantar Pustulosis Key Companies
15. Palmoplantar Pustulosis Key Products
16. Dormant and Discontinued Products
17. Palmoplantar Pustulosis Unmet Needs
18. Palmoplantar Pustulosis Future Perspectives
19. Palmoplantar Pustulosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Palmoplantar Pustulosis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/palmoplantar-pustulosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=palmoplantar-pustulosis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-kyowa-kirin-co-ltd-aristea-therapeutics-inc-anaptysbio-inc-boeh]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Palmoplantar Pustulosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Kyowa Kirin Co., Ltd., Aristea Therapeutics Inc., AnaptysBio, Inc., Boeh here
News-ID: 4132316 • Views: …
More Releases from ABNewswire
Cell and Gene Therapies in Rare Disorders Market to Evolve Rapidly Over the Next …
The Key Cell and Gene Therapies in Rare Disorders Companies in the market include - REGENXBIO, Coave Therapeutics, GenSight Biologics, Ultragenyx, Pfizer, Sangamo Therapeutics, Roche, 4D Molecular Therapeutics, Astellas Gene Therapie, Actus Therapeutics, Nanoscope Therapeutics, Ocugen, jCyte, Amicus Therapeutics, Capricor Therapeutics, Nippon Shinyaku, Brainstorm Cell Therapeutics, Editas Medicine, Abeona Therapeutics, Ishin Pharma, and others.
DelveInsight's "Cell and Gene Therapies in Rare Disorders Market Insights, Epidemiology, and Market Forecast-2034 report offers an…
Cruelty.Farm: Uncovering the Truth About Animal Agriculture and Inspiring a Glob …
When it comes to the food we eat, few people stop to think about what happens before a piece of meat reaches their plate. The global food system - dominated by industrial animal agriculture - has quietly become one of the most destructive forces on the planet. From deforestation and pollution to animal suffering and public health crises, the hidden costs are immense.
This is the reality that Cruelty.Farm seeks to…
Waka Flocka Flame to Headline Nightly College Tour Launch in Austin
Waka Flocka Flame will headline the launch of the Nightly College Tour at Empire Garage in Austin, TX on November 13, 2025. The event marks Nightly's official debut in Austin and kicks off a nationwide college tour blending music, culture, and community.
Waka Flocka Flame will headline the official launch of the Nightly College Tour on Thursday, November 13, 2025 at Empire Garage in Austin, TX. The concert brings one of…
Lambert Eaton Myasthenic Syndrome Market Positioned for Accelerated Development …
The Key Lambert Eaton Myasthenic Syndrome Companies in the market include - Jacobus Pharmaceutical, Catalyst Pharmaceuticals, and others.
DelveInsight's "Lambert Eaton Myasthenic Syndrome Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Lambert Eaton Myasthenic Syndrome, historical and forecasted epidemiology as well as the Lambert Eaton Myasthenic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail…
More Releases for Palmoplantar
Palmoplantar Keratoderma (PPK) market is expected to reach USD 2.4 billion by 20 …
Palmoplantar keratoderma (PPK) refers to a group of skin disorders characterized by thickened skin on the palms and soles due to abnormal keratinization. PPK can be inherited or acquired, with symptoms ranging from mild thickening to painful fissures that significantly impair quality of life. While most cases are rare, the burden on patients is substantial, often requiring lifelong management.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71429
Growing awareness of…
Palmoplantar Pustulosis Market is expected to reach USD 4.8 billion by 2034
Palmoplantar pustulosis (PPP) is a rare, chronic, and debilitating inflammatory skin disease characterized by recurring sterile pustules on the palms and soles. PPP significantly impairs quality of life due to pain, itching, and functional limitations. Traditionally managed with corticosteroids and systemic immunosuppressants, the disease remains difficult to treat, with high relapse rates and limited therapeutic options.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71387
In recent years, however, the market…
Strong Growth Ahead: Palmoplantar Pustulosis Market Size To Grow At Arecord 7.9% …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Big Is the Palmoplantar Pustulosis Market Size Expected to Be by 2034?
The market for palmoplantar pustulosis has seen significant expansion in the past few years. The market, which is set to progress from $1.93 billion in 2024 to $2.10 billion in 2025, is expected to experience a compound annual growth rate (CAGR)…
Palmoplantar Keratoderma Market Growth 2025: Trends, Consumer Demand, and Key Op …
The Latest research report on the Palmoplantar Keratoderma Market 2025 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2032. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Palmoplantar Keratoderma Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies, market dynamics,…
Strong Growth Ahead: Palmoplantar Pustulosis Market Size To Grow At Arecord 7.9% …
The Palmoplantar Pustulosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Palmoplantar Pustulosis Market Size Expected to Be by 2034?
In recent times, the market size for palmoplantar pustulosis has seen considerable growth. It's expected to rise from $1.93 billion in 2024…
Japan Palmoplantar Pustulosis (PPP) Market Size, Company Profiles and Key Figure …
Japan Palmoplantar Pustulosis (PPP) market analysis report encompasses many vital parameters about market analysis which can be used for the business. Analysis and estimation of important industry trends, market size, and market share are mentioned in this industry report. The report helps to measure and optimize each step in the lifecycle of industrial process including engagement, acquisition, retention, and monetization. Japan Palmoplantar Pustulosis (PPP) business research report is prepared by…
